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Background: CpG island aberrant methylation is shown to be an important mechanism in gene silencing. The
important role of IL-17 in inflammatory response to H. pylori colonization has been indicated. We investigated the
influence of IL17A polymorphisms, -197 G>A (rs2275913) and *1249 C> T (rs3748067), on the methylation of DAPK
and CDH1.
Methods: Gastric mucosal samples were obtained from 401 subjects without malignancies. Methylation status of
gene was determined by MSP. The genotyping of IL17A was performed by PCR-SSCP.
Results: Methylations of DAPK and CDH1 were seen in 196 and 149 of all 401 subjects, respectively. Overall,
*1249 T carrier was associated with a decreased risk for DAPK methylation, whereas -197 G>A was not. In the
subjects older than 60 years old, *1249 T carrier was more strongly associated with gene methylation and -197 A
carrier tended to be associated with an increased risk for CDH1 methylation. When evaluating by inflammation
promoting haplotype (-197 mutant carrier with *1249 homozygote), this haplotype had a more strongly increased
risk for both DAPK and CDH1 methylations in comparatively older subjects. Both atrophy and metaplasia scores
were significantly increased with age in -197 A carrier or *1249 CC homozygote, whereas were not in -197 GG
homozygote or *1249 T carrier. PG I/II ratio was more significantly decreased in -197 A carrier than in GG
homozygote under influence of H. pylori infection.
Conclusions: In -197 A allele carrier with *1249 CC homozygote, the methylations of both DAPK and CDH1 may be
increased gradually, but more rapidly than the other genotypes, with age and altered gastric mucosal structure
induced by H. pylori infection.
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Interleukin-17 (IL-17) is a relatively newly described
cytokine that bridges the adaptive and innate immune
systems. IL-17A is a cytokine responsible for the patho-
genic activity of the Th17 cells [1], a distinct lineage of
CD4+ effector cells [2]. IL-17A induces multiple proin-
flammatory mediators, including chemokines, cytokines,
and metalloproteinases, from epithelial and fibroblast
cells [3]. An enhanced expression of IL-17 has been also
documented and implicated in the pathogenesis of* Correspondence: tarisawa@kanazawaed.ac.jp
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reproduction in any medium, provided the orimmune-mediated diseases, such as rheumatoid arthritis,
multiple sclerosis, and psoriasis [4]. In addition, IL-17
has the ability to stimulate IL-8 production in both epi-
thelial cells and macrophages [5,6], raising the possibility
that this cytokine may play an important role in the re-
cruitment of inflammatory cells during bacterial infec-
tions. At first, Lussa et al. reported that bio-active Il-17A
production was increased during Helicobacter pylori
(H. pylori) infection, suggesting the possibility that this
cytokine may play an important role in the H.pylori-
induced inflammatory response [7]. Thereafter, several
studies reported that IL-17 stimulates IL-8 release by
gastric epithelial cells and facilitates the chemotaxis of
neutrophils through an IL-8-dependent mechanism,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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H. pylori-colonized gastric mucosa [8-10].
On the other hand, gastric cancer is one of the most
common cancers worldwide [11,12], but the etiology of
this tumor remains unclear. H. pylori infection is now
accepted as a crucial event in the development of peptic
ulcer disease and atrophic gastritis, and it is implicated
in the development of gastric carcinoma, especially not
located in cardia [13-15]. Several cancers, including gas-
tric tumors, show methylations of multiple genes includ-
ing E-cadherin gene (CDH1), death-associated protein
kinase gene (DAPK) and CDKN2A [16,17]. Some genes
are also methylated in non-neoplastic tissues with aging,
and this alteration is known as age-related methylation
[18,19]. In addition, it has also shown that gene methyla-
tion may be present in chronic inflammation of various
tissues [20,21]. In gastric mucosa, it was indicated that
methylation of CpG island was induced by H. pylori in-
fection in non-cancerous mucosa [22,23] and considered
as the precancerous conditions in gastric carcinogenesis
[24]. Among several genes, DAPK and CDH1, as well as
CDKN2A, are frequently methylated in non-neoplastic
gastric mucosa in relation to age, H. pylori infection,
histological degree of gastritis, and gastric carcinogenesis
[22,25,26].
Recently, we have reported that the IL-17A gene (IL17A)
polymorphism (rs2275913 G>A) and IL-17 F gene
(IL17F) polymorphism (rs763780 T>C) are closely asso-
ciated with the susceptibility to gastric carcinogenesis [27],
as well as ulcerative colitis [28]. Thereafter, several studies
revealed the association between IL17A rs2275913 G>A
and rheumatoid arthritis, gastric carcinogenesis and
asthma [29-31]. The rs2275913 (G/A), located at a pos-
ition -197 from the starting codon of IL17A, may regulate
the expression of mRNA. In addition, there is a poly-
morphism rs3748067 (*1249 C>T) in IL17A 3’-UTR, tar-
geted by some microRNAs. We hypothesize that these
IL17A gene polymorphisms may influence the develop-
ment of aberrant DNA mathylation of gastric mucosa.
In the present study, we investigated the association be-
tween polymorphisms of IL17A, rs2275913 (-197 G>A)
and rs3748067 (*1249 C>T), and the aberrant DNA




The studied population comprised 401 subjects without
gastric malignancies recruiting the Endoscopy Center of
Fujita Health University Hospital or Kanazawa Medical
University Hospital. In HapMap-JPT, the frequency of
IL17A -197 A allele frequency was 45.3%. We assume that
a 20% decrease in the prevalence of an allelic frequency
would be clinical relevance (unmethylated group: 40% vs.methylated group: 50%). Assuming an alpha value = 0.05
and a power = 0.80, at least 200 unmethylated subjects
and 200 methylated subjects would be sufficient to iden-
tify a clinical relevant difference. Accordingly, 400 sub-
jects would be clinical relevance for the study. All
subjects underwent upper endoscopy with one or two bi-
opsy specimens from non-cancerous mucosa in antrum.
Parts of each specimen was fixed in 10% buffered forma-
lin and embedded in paraffin, while the other part was
immediately frozen and stored at -80°C. Later, Genomic
DNA was isolated from frozen specimens using protein-
ase K. A specimen from the subjects who consented to
only one biopsy was not used for the histological
evaluation.
The subjects without methylation of both DAPK and
CDH1 were classified into non CIHM (CpG island high
methylated) group, whereas the others except non
CIHM were classified into CIHM group. Furthermore,
the subjects were divided into 2 groups by genotype as
follows:
HR (high risk) group: IL17A -197 A carrier with *1249
CC genotype
LR (low risk) group: the subjects except HR group
The Ethics Committees of the Fujita Health University
and Kanazawa Medical University approved the protocol,
and prior, written informed consent was obtained from
all participating subjects.
Bisulfate modification and Methylation-Specific PCR (MSP)
To examine DNA methylation, genomic DNA was trea-
ted with sodium bisulfite using BislFast DNA Modification
Kit for Methylated DNA Detection (TOYOBO, Co., Ltd.,
Osaka, Japan). MSP for DAPK and CDH1 were carried out
using the methods reported by Katzenellenbogen et al.
[32] and Herman et al. [33], respectively. In brief,
MSP reactions were carried out with primer pairs
described below, using EX Taq HS (Takara Bio, Inc.,
Shiga, Japan).
Primer pairs:
DAPK: methylated forward; 5’-ggatagtcggatcgagttaacgtc-3’,
reverse; 5’-ccctcccaaacgccga-3’,
DAPK: unmethylated forward; 5’-ggaggatagttggattgagtta
atgtt-3’,reverse; 5’-caaatccctcccaaacaccaa-3’
CDH1: methylated forward; 5’-ttaggttagagggttatcgcgt-3’,
reverse; 5’-taactaaaaattcacctaccgac-3’,
CDH1: unmethylated forward; 5’-taattttaggttagagggttat
tgt-3’,reverse; 5'-cacaaccaatcaacaacaca-3’,
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using DNA from peripheral blood of a young individual
without H. pylori infection and DNA methylated with SssI
methylase (NEW ENGLAND BioLabs Inc., Beverly, MA).
The MSP was carried out in a volume of 20μL containing
0.1 μg of bislufite-modificated DNA. The bands of MSP
were detected by electrophoresis in 3.0% agarose gels
stained with ethdium bromide. Hyper-methylation was
defined as the presence of a positive methylation band
showing signals approximately equal to or greater than
that of the size marker (10 ng/ μL: 100 bp DNA Ladder,
Takara Bio, Inc., Shiga, Japan) regardless of the presence of
unmethylated bands.Table 1 Characteristics of the subjects and frequency of
genotypes
Total non CIHM CIHM p value*
number of subjects 401 153 248
mean age± SD 60.0 ± 13.8 60.2 ± 13.7 59.9 ± 13.9 NS
male : female 230 : 171 87 : 66 143 : 105 NS
H. pylori positive rate 241/401 71/153 170/248 <0.0001
-197 G>A
GG 155 65 90
GA 204 74 130
AA 41 14 27Genotyping of polymorphisms
The DNA isolated from biopsy specimens or peripheral
blood was used. Polymorphism was genotyped by PCR-
SSCP method as reported previously [27,28]. To detect
IL-17A *1249 C>T using the primer pairs (1249F: 5’-c
ccctcagagatcaacagaccaaca-3’and 1249R: 5’-gcgaaaatggttac
gatgtgaaacttg-3’), PCR was carried out in a volume of
20 μL containing 0.1 μg of genomic DNA. The DNA
was denatured at 95°C for 3 minutes, followed by 35
cycles at 95°C for 30 seconds, 52°C for 40 seconds,
and 72°C for 45 seconds, with final extension at 72°C
for 5 minutes. Thereafter, 2 μL of the PCR product was
denatured with 10 μL of formamide (Sigma-Aldrich Co.,
St. Louis, USA) at 90°C for 5 minutes. SSCP was carried
out at 18°C using a GenePhor DNA separation system
with GeneGel Excel 12.5/24 (Amersham Biosciences
Corp., USA), after which the denatured single strand
DNA bands were detected using a DNA Silver Staining
Kit (Amersham Biosciences Corp.).
To detect IL-17A -197 G>A, using the primer pairs
(IL17AF: 5’-aacaagtaagaatgaaaagaggacatggt-3’ and IL17AR:
5’-cccccaatgaggtcatagaagaatc-3’), PCR was carried out in a
volume of 20 μL containing 0.1 μg of genomic DNA. The
DNA was denatured at 96°C for 90 s, followed by 35 cycles
at 96°C for 15 s, 58°C for 30 s, and 72°C for 45 s, with final
extension at 72°C for 3 min. Thereafter, SSCP was carried
out at 6°C as a same manner described above.(unknown) 1 0 1
A allele frequency 35.8% 33.3% 37.2% NS
*1249 C> T
CC 340 124 216 0.058a
CT 42 20 22Histological evaluation
In 286 of 401 subjects, the severity of chronic gastritis
was classified according to the updated Sydney system
[34] by a pathologist who had no access to any clinical
information.TT 16 9 7
(unknown) 3 0 3
T allele frequency 9.3% 12.4% 7.3% 0.023
non CIHM: neither DAPK nor CDH1 were methylated.
CIHM: both or either DAPK or CDH1was methyaled.
*: unmethylated vs. methylated.
a: frequency of *1249 CC genotype.Serological evaluation
The pepsinogen (PG) I/II ratio was calculated based on
the data of the serum PG I and PG II levels measured by
radioimmunoassay in 74 of 401 subjects. A PG I/II ratio
that showed a decrease in proportion to the severity ofgastric mucosal atrophy was used as a marker of atrophic
gastritis [35,36].
Statistical analysis
The data were expressed as mean ± SD. Mean ages be-
tween 2 groups was compared by Student’s t-test. The
ratio of H. pylori infection status and male/female was
compared by Fisher’s exact test. Allele and genotype fre-
quencies were calculated by direct counting. The allele
counts were also compared by a Fisher’s exact test. The
strength of association between allele frequencies and
the disease was assessed by calculating the odds ratio
(OR) and 95% confidence intervals (CI) by logistic re-
gression analysis. Adjusted ORs were calculated after ad-
justment for age, gender and H. pylori infection status.
Each updated Sydney system score and PG I/II ratio be-
tween 2 groups were compared by Mann Whitney U-test
. The relationship between age and updated Sydney sys-
tem score was assessed by ANCOVA. When setting
α= 0.05, the β value was calculated by Post-hoc analysis.




The characteristics of subjects were summarized in
Table 1. H. pylori positive ratio was significantly higher
in CIHM group than in non CIHM group. The
Table 2 Distributions of IL17A genotypes and gene mathylations
DAPK CDH1
Unmethylated methylated p value* unmethylated methylated p value*
number of subjects 205 196 252 149
mean age± SD 59.3 ± 13.6 60.8 ± 13.9 NS 60.1 ± 14.1 59.9 ± 13.2 NS
male : female 118 : 87 112 : 84 NS 145 : 107 85 : 64 NS
H. pylori positive rate 104/205 137/196 <0.0001 131/252 110/149 <0.0001
-197 G>A
GG 86 69 98 57
GA 99 105 128 76
AA 19 22 26 15
(unknown) 1 0 0 1
A allele frequency 33.6% 38.0% NS 35.7% 35.8% NS
*1249 C> T
CC 167 173 0.023a 210 130
CT 28 14 28 14
TT 10 6 11 5
(unknown) 0 3 3 0
T allele frequency11. 7% 6.7% 0.020 10.0% 8.2% NS
*: unmethylated vs. methylated.
a: frequency of *1249 CC genotype.
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group was 65GG, 74GA and 14AA. It was in the
Hardy-Weinberg equilibrium (p=0.36). That of *1249 C>T
was 124cm3, 20CT and 9TT, which was not in the Hardy-
Weinberg equilibrium. The distribution of -197 G>A
genotype was not different among two groups. However,
the frequencies of *1249 minor allele was significantly
lower in CIHM group than non CIHM group (p=0.023,
1-βpower= 0.636).
Distributions of IL17A genotypes and gene mathylations
The H. pylori positive ratio was significantly higher in
methylated group than in unmethylated group of DAPK
or CDH1 (Table 2). The distribution of -197 G>A geno-
type was not different among two groups of both genes,Table 3 Association between IL17A -197 G>A polymorphism
CIHM (DAPK or CDH1) GG GA AA
unmethylated (153) 65 74 14
methylated (248) 90 130 27
DAPK
unmethylated (205) 86 99 19
methylated (196) 69 105 22
CDH1
unmethylated (252) 98 128 26
methylated (149) 57 76 15
by logistic regression analysis after adjustment for age, gender and H. pylori infectio
( ): number of subjects.whereas the frequency of *1249 CC homozygote was sig-
nificantly higher in methylated group than in unmethy-
lated group of DAPK (p = 0.023). In addition, the minor
allele frequency was significantly lower in methylated
group than in unmethylated group of DAPK (p= 0.020,
1-βpower=0.641). However, the distribution of *1249 C>T
genotype was not different among two groups of
CDH1.
Risk of IL17A polymorphisms for the gene methylation
The -197 G>A was not associated with CIHM and was
not associated with each DAPK and CDH1 methylations
(Table 3). On the other hand, *1249 C>T tended to be
associated with CIHM (OR, 0.611; 95%CI, 0.343-1.09;
p = 0.096, Table 4). Meanwhile, *1249 mutant carrier hadand gene methylation
unknown A carrier vs. GG; OR (95%CI) p value
0 reference -
1 1.33 (0.870-2.04) 0.19
1 reference -
0 1.37 (0.907-2.08) 0.13
0 reference -
1 1.04 (0.676-1.60) 0.86
n status.
Table 4 Association between IL17A *1249 C> T polymorphism and gene methylation
CIHM (DAPK or CDH1) CC CT TT unknown T carrier vs. CC; OR (95%CI) p value
unmethylated (153) 124 20 9 0 reference -
methylated (248) 216 22 7 3 0.611 (0.343-1.09) 0.096
DAPK
unmethylated (205) 167 28 10 0 reference -
methylated (196) 173 14 6 3 0.513 (0.282-0.933) 0.028
CDH1
unmethylated (252) 210 28 11 3 reference -
methylated (149) 130 14 5 0 0.856 (0.466-1.57) 0.62
by logistic regression analysis after adjustment for age, gender and H. pylori infection status.
( ): number of subjects.
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tion (OR, 0.513; 95%CI, 0.282-0.933; p = 0.028), and had
no significant risk for the development of CDH1 methy-
lation (p = 0.62, Table 4).
Because mean age of our subjects was approximately
60 years old and gene methylation is increased with
aging, we made further assessment in the subjects older
than 60 years old. Then, -197 A carrier had an increased
risk for the development of CIHM (OR, 1.80; 95%CI,
1.01-3.19; p = 0.046), conversely *1249 T carrier had a
decreased risk (OR, 0.463; 95%CI, 0.224-0.959; p = 0.038,
Table 5). When assessing the risk for each DAPK andTable 5 Risk of IL17A plymorphisms for gene methylation in
CIHM (DAPK or CDH1)
IL17A -197 G>A GG GA AA
unmethylated (83) 38 39 6
methylated (143) 46 79 18
IL17A *1249 C> T CC CT TT
unmethylated (83) 63 15 5
methylated (143) 124 13 5
DAPK
IL17A -197 G>A GG GA AA
unmethylated (103) 44 50 9
methylated (123) 40 68 15
IL17A *1249 C> T CC CT TT
unmethylated (103) 79 19 5
methylated (123) 108 9 5
CDH1
IL17A -197 G>A GG GA AA
unmethylated (145) 60 71 14
methylated (81) 24 47 10
IL17A *1249 C> T CC CT TT
unmethylated (145) 116 22 6
methylated (81) 71 6 4
by logistic regression analysis after adjustment for age, gender and H. pylori infectio
( ): number of subjects.CDH1 methylation, -197 A carrier tended to have an
increased risk for the development of CDH1 methylation
(p = 0.068), whereas *1249 T carrier had a decreased risk
for the development of DAPK methylation (OR, 0.427;
95%CI, 0.204-0.893; p = 0.024).
When assessing the risk of HR (-197 A carrier with
*1249 CC genotype), HR tended to have an increased
risk for CIHM (p= 0.081), and had a significantly
increased risk for the development of DAPK methyta-
tion (OR, 1.57; 95%CI, 1.04-2.35; p = 0.031, Table 6).
In the subjects older than 60 years old, HR had an
increased risk for CIHM (OR, 1.93; 95%CI, 1.10-3.39;the subjects older than 60 years old
unknown A carrier vs. GG; OR (95%CI) p value
0 reference -
0 1.80 (1.01-3.19) 0.046
unknown T carrier vs. CC; OR (95%CI) p value
0 reference -
1 0.463 (0.224-0.959) 0.038
unknown A carrier vs. GG; OR (95%CI) p value
0 reference -
0 1.57 (0.897-2.75) 0.11
unknown T carrier vs. CC; OR (95%CI) p value
0 reference -
1 0.427 (0.204-0.893) 0.024
unknown A carrier vs. GG; OR (95%CI) p value
0 reference -
0 1.76 (0.958-3.22) 0.068
unknown T carrier vs. CC; OR (95%CI) p value
1 reference -
0 0.590 (0.263-1.32) 0.20
n status.
Table 6 Risk of rs2275913 and rs3748067 for gene methylations
CIHM (DAPK or CDH1)
over all HR LR unknown HR vs. LR; OR (95%CI) p value
unmethylated (153) 76 77 0 reference -
methylated (248) 144 101 3 1.45 (0.955-2.20) 0.081
60 =<
unmethylated (83) 38 45 0 reference -
methylated (143) 89 54 0 1.93 (1.10-3.39) 0.023
DAPK
over all HR LR unknown HR vs. LR; OR (95%CI) p value
unmethylated (205) 102 102 1 reference -
methylated (196) 118 76 2 1.57 (1.04-2.35) 0.031
60 =<
unmethylated (103) 49 54 0 reference -
methylated (123) 78 45 0 1.91 (1.10-3.30) 0.021
CDH1
over all HR LR unknown HR vs. LR; OR (95%CI) p value
unmethylated (252) 134 116 2 reference -
methylated (149) 86 62 1 1.20 (0.787-1.83) 0.40
60 =<
unmethylated (145) 73 72 0 reference -
methylated (81) 54 27 0 2.01 (1.12-3.62) 0.020
DAPK and CDH1
over all HR LR unknown HR vs. LR; OR (95%CI) p value
unmethylated (304) 160 141 3 reference -
methylated (97) 60 37 0 1.44 (0.890-2.34) 0.14
60 =<
unmethylated (165) 84 81 0 reference -
methylated (61) 43 18 0 2.42 (1.25-4.68) 0.0087
HR: -197 A carrier with*1249 CC genotype, LR: the others by logistic regression analysis after adjustment for age, gender and H. pylori infection status.
( ): number of subjects.
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ment of each DAPK methylation and CDH1 methyla-
tion (OR, 1.91; 95%CI, 1.10-3.30; p = 0.021 and OR,
2.01; 95%CI, 1.12-3.62; p = 0.020, respectively). In
addition, HR had a more increased risk for the devel-
opment of the methylation of both two genes (OR,
2.42; 95%CI, 1.25-4.68; p = 0.0087, 1-βpower = 0.709).
Association between IL17A polymorphisms and
histological or serological gastric mucosal atrophy
Both atrophy and metaplasia scores were strongly corre-
lated to the age in -197 A carrier (p = 0.0012 and 0.0097
by ANOVA, respectively, Figure 1), whereas there was
no correlation between age and both scores in GG
homozygote (p = 0.092 and p= 0.73, respectively). Both
scores were also strongly correlated to the age in *1249CC homozygote (p = 0.0022 and 0.0064, respectively,
Figure 2), whereas only atrophy score was weakly cor-
related to the age in T carrier (p = 0.044).
PG I/II ratio was significantly lower in H. pylori posi-
tive subjects than negative subjects in both -197 A car-
rier and GG homozygote, but in the former more
strongly significant (p = 0.0017 and 0.018, respectively,
Figure 3). The association between *1249 C>T and PG
I/II ratio could not be evaluated, because the number of
T carrier assessed was very small.
Discussion
Previously, we found no association between IL17A -
197 G>A and methylation of both DAPK and CDH1
[37]. In the present study with a large number of sub-
jects, we confirm these results. However, our present
Figure 1 Association between gastric mucosal atrophy and IL17A -197 G>A polymorphism. Both atrophy and metaplasia scores were
significantly correlated to the age in A carrier (mutant carrier), whereas not in GG homozygote (wild homozygote).
Figure 2 Association between gastric mucosal atrophy and IL17A *1249 C> T polymorphism. Both atrophy and metaplasia scores were
significantly correlated to the age in CC homozygote (wild homozygote), whereas only atrophy score was correlated to the age, but weakly,
in T carrier (mutant carrier).
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Figure 3 Change of PG I/II ratio under the influence of H. pylori infection by IL17A -197 G>A genotype. PG I/II ratio was significantly
lower in H. pylori positive subjects than negative subjects in both -197 A carrier and GG homozygote, but in the former more strongly significant.
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an increased risk for the development of methylation, es-
pecially of CDH1, in the subjects older than 60 years old.
In addition, the association of *1249 C>T located in 3’-
UTR was also investigated in the present study. The
*1249 T carrier was an increased risk factor for DAPK
methylation and more strongly associated with the
increased risk for gene methylation in comparatively
older subjects (60 years =<). Over all, *1249 C>T
seemed to be more closely associated with gene methyla-
tion than -197 G>A. When assessing the association of
IL17A haplotype, -197 mutant (A allele) carrier with
*1249 wild homo alleles (CC homozygote) had a more
strongly increased risk for the development of gene
methylation. Because allele frequency was less than prior
assumptions, study population has been rather small.
Therefore, the effect of type II error cannot be excluded
in the assessment of allelic or genotype association of
polymorphisms with gene methylation. This is one of the
major limitations in our study.
Although the mechanisms of gene methylation are un-
known, several factors may contribute to this methylation,
such as exogenous carcinogens, generated reactive oxygen
and host genetic differences [38]. One of the most import-
ant factors causing gene methylation in stomach is H. pylori
infection [17], which first induces chronic superficial gastri-
tis, which can progress to chronic atrophic gastritis, intes-
tinal metaplasia, and dysplasia that leads toward gastric
carcinoma [39]. In facts, the methylation of certain genes in
non-neoplastic gastric mucosa correlate with H. pylori
related histological or serological severity of gastritis [26]
and gastric cancer occurrence [23,40,41]. IL-17A promotes
the gastric mucosal inflammation via increased IL-8production [8-10]. In addition, IL-17A induces increased
levels of reactive oxygen species, which is one of the
major inflammatory mediators [42]. Methylation of cyto-
sine residues in DNA can be greatly influenced by hy-
droxyl free radical adducts on adjacent guanine residues
[43]. IL-17A may contribute to increased gene methylation
in H. pylori-induced gastric inflamed mucosa through
these mechanisms.
Recently, it has been also reported that IL17A -197 AA
homozygote is associated with several asthma-related
traits and confers genetic susceptibility to childhood
asthma in Chinese [31]. Furthermore, in our present study,
both atrophy and metaplasia scores increased with age in -
197 A carrier, whereas did not in GG homozygote. PG I/II
ratio was more significantly decreased by H. pylori infec-
tion in A carrier than GG homozygote. In general, gastric
mucosal atrophy develops as a result of severe inflamma-
tion that continued for a long term [39]. These suggest
that IL17A -197 A allele may promote the inflammation.
However, we found no significant difference of inflamma-
tion score among genotypes (data not shown). The degree
of inflammation seems to fluctuate according to the in-
flammatory environment and is decreased with the pro-
gression of gastric mucosal atrophy. Therefore, it may be
difficult to determine the degree of inflammation at one
point. On the other hand, there is the possibility that
IL17A polymorphisms may be associated with gastric mu-
cosal atrophy by the mechanism other than promoting the
inflammation. It is interesting to understand the effect of -
197 A allele on the expression of IL-17A. Chen et al.
demonstrated that IL17A -197 G>A was not related to
PHA induced IL-17 production in PBMCs [31]. However,
many kinds and subtypes of cells existed in PBMCs and
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production were complicated. In addition, IL-17A seemed
to have dual actions, inflammatory or protective, depend-
ing of the co-expression of other cytokines [44]. Therefore,
the function of IL17A -197 G>A in the inflammation is
still well unknown.
On the other hand, to our best knowledge, there have
been no reports of the association between IL17A
*1249 C>T, located in 3’-UTR, and human disorders. In
general, microRNAs post-transcriptionally regulate the
expression of mRNA through the binding to 3’-UTR of
target genes. Therefore, altered conformation of 3’-UTR
may affect the binding of microRNAs to mRNA. In our
present study, *1249 mutant carrier had a decreased risk
for gene methylation, especially DAPK, in comparative
older subjects. Moreover, it seemed that the repressor ac-
tivity of *1249 T allele took part in the inflammations
more strongly than the stimulatory effects of -197 A al-
lele. In addition, both atrophy and metaplasia scores
increased with age in *1249 wild homozygote (CC geno-
type), whereas only atrophy score weakly correlated to
the age in mutant carrier. These suggest that *1249 T al-
lele may protect the inflammation. That is, we speculate
that IL17A -197 mutant allele may promote and *1249
mutant allele may protect the inflammation.
Based on these results, we evaluated the association of
HR, as an inflammation promoting haplotype, (-197 mu-
tant carrier with *1249 wild homozygote) with gene
methylation. In the subjects older than 60 years old, HR
was more strongly associated with the increased risk for
both DAPK and CDH1 methylation, although overall
with only DAPK methylation. This suggests that both -
197 G>A and *1249 C>T may affect on the expression
or function of IL-17A coordinately. The reason why sig-
nificant differences were observed in comparatively older
subjects may be because gene methylation is age-related
change and/or because methylation depends on severity
and periods of chronic inflammation. We speculate that
this difference becomes clear after gene methylation pro-
gressed at the old age.
Conclusions
In conclusions, the inflammation promoting allele of IL17A
-197 G>A (rs2275913) and *1249 C>T (rs3748067) was
significantly associated with the increased risk for the devel-
opment of gene mathylations in non-cancerous gastric mu-
cosa. That is, in -197 A allele carrier with *1249 CC
homozygote, the methylation of DAPK and CDH1 is
increased gradually, but more rapidly, with age and altered
gastric mucosal structure induced by H. pylori infection
than in the others.
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